KU ADC Mitochondrial Genomics and Metabolism Core Supplement

$381,871P30FY2019AGNIH

University Of Kansas Medical Center, Kansas City KS

Investigators

Linked publications & trials

Paper 39649607 Paper 39606325 Paper 39379761 Paper 39289471 Paper 39254167 Paper 39207439 Paper 39173101 Paper 38980643 Paper 38958543 Paper 38949538 Paper 38915636 Paper 38867031 Paper 38858380 Paper 38721926 Paper 38712163 Paper 38641585 Paper 38633788 Paper 38621995 Paper 38460116 Paper 38441951 Paper 38425303 Paper 38423160 Paper 38418871 Paper 38244935 Paper 38194584 Paper 38146639 Paper 38124277 Paper 38035268 Paper 37991017 Paper 37804609 Paper 37791031 Paper 37681845 Paper 37592813 Paper 37580727 Paper 37557082 Paper 37491248 Paper 37474615 Paper 37436187 Paper 37397072 Paper 37322115 Paper 37260021 Paper 37245492 Paper 37212281 Paper 37212114 Paper 37171062 Paper 37066917 Paper 37057867 Paper 37051669 Paper 37038809 Paper 36997127 Paper 36979320 Paper 36970907 Paper 36946449 Paper 36944170 Paper 36872574 Paper 36847010 Paper 36847003 Paper 36840665 Paper 36822187 Paper 36758620 Paper 36722399 Paper 36710677 Paper 36710669 Paper 36688439 Paper 36681388 Paper 36648159 Paper 36628434 Paper 36621368 Paper 36617779 Paper 36577280 Paper 36565204 Paper 36564192 Paper 36530083 Paper 36516926 Paper 36482861 Paper 36462447 Paper 36394443 Paper 36324086 Paper 36314203 Paper 36308307 Paper 36268684 Paper 36264254 Paper 36255379 Paper 36253382 Paper 36251929 Paper 36220593 Paper 36189595 Paper 36178120 Paper 36155505 Paper 36154934 Paper 36097795 Paper 36093697 Paper 36062452 Paper 36031904 Paper 36031892 Paper 35960268 Paper 35894783 Paper 35871325 Paper 35842477 Paper 35802628

Abstract

PROJECT SUMMARY This Administrative Supplement requests one year of funding to support unforeseen costs associated with the University of Kansas Alzheimer?s Disease Center (KU ADC) Mitochondrial Genomics and Metabolism (MGM) Core. MGM Core activities span a spectrum from fundamental mitochondrial biology research that addresses AD etiology and pathogenesis, to clinical trials that assess lifestyle and pharmacologic intervention impact. An unanticipated growth in the number of investigators requesting MGM Core support, and an emergent unforeseen need for the Core to develop new biomarker infrastructure, predicates this request. With respect to MGM biomarker-related activities, mitochondrial target engagement biomarkers newly developed and validated by the MGM Core in actual clinical studies spurred unanticipated clinical trial growth. This put further service demands on the Core, and generated opportunities to develop additional target engagement biomarkers. As an extension of this, we realize a need to extend our biomarker development efforts to cerebrospinal fluid (CSF). Accomplishing this requires critical infrastructure expansion. Also, partly due to our successes, increased NIA AD research pay lines, and technology advances the volume of service requests we currently receive exceeds what we planned for. To strategically address these unforeseen needs and capitalize on unanticipated opportunities, support through this Administrative Supplement will help us: (1) expand induced pluripotent stem cell (iPSC) infrastructure, as well as blood-based mitochondrial biomarker measurement and development throughput; (2) develop and provide CSF mitochondrial biomarker measurements; and (3) establish a biomarker dataset linked to clinical, genomic, and biospecimen data. We can achieve these aims in one year by supporting effort for a laboratory technician and a physician extender who performs lumbar punctures on Clinical Cohort participants. Funds to support other personnel pertinent to these efforts are also requested.

View original record on NIH RePORTER →